Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to validate the ability to assess the genetic differences (DNA fingerprinting) on polar bodies (excess genetic material given off from the egg) and cells so that this technique may be used in the future to confirm markers of reproductive competence and improve the efficiency and safety of clinical human in vitro fertilization.
| Condition | Intervention |
|---|---|
|
DNA Fingerprinting |
Other: Polar body and embryo biopsy |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Validation of the Accuracy of DNA Fingerprinting Using Polar Bodies and Embryonic Cells |
- Validate DNA fingerprinting [ Time Frame: After delivery of infant(s) ] [ Designated as safety issue: No ]Comparison of the SNP profile from the buccal swab as compared to the SNP profile of the 1st polar body biopsy, the SNP profile of the 2nd polar body biopsy and the SNP profile of the embryo biopsy will show which biopsy provides the greatest predictive value of the DNA of the conceptus.
| Enrollment: | 100 |
| Study Start Date: | January 2008 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Study Group
All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
|
Other: Polar body and embryo biopsy
2 polar bodies and all embryos will be biopsied prior to embryo transfer.
Other Names:
|
Detailed Description:
Our group has recently validated a technique involving whole genomic amplification followed by single nucleotide polymorphisms (SNP) analysis which allows DNA fingerprinting of single cells. Given that there are more than 3.3 billion base pairs that constitute the human genome, there are approximately 3 million sites where routine variation in the genetic code exists. These SNPs have been identified on average to occur approximately once every 1000 base pairs (bp) and are present on all chromosomes.
100 couples will undergo routine in vitro fertilization (IVF) stimulation, the protocol to be determined by the patient's primary doctor. Following oocyte retrieval and intracytoplasmic sperm injection (ICSI), the first polar body will be biopsied using standard laboratory procedures, and sent for genetic analysis. 24 hours later, the second polar body will be biopsied and sent for genetic analysis. Finally, the embryos will be biopsied prior to transfer and the cell will be sent for gentic analysis. Genetic results are not available prior to transfer and there are be no delays in the treatment schedule as a result of the study. Buccal swabs are collected from infants. SNP profiles are created from the polar body and embryo biopsies which are then compared to the SNP profiles created from the buccal swabs.
Eligibility| Ages Eligible for Study: | 21 Years to 43 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Major Inclusion: The following are major inclusion criteria:
- Maximum of one prior failed IVF treatment cycle
- Female partner less than 43 years of age
- Normal day 3 FSH level (<12 mIU/mL)
- Basal antral follicle count greater than or equal to 8
- Ejaculated sperm specimen from the male partner with greater than 100,000 total motile
- Donor sperm okay if patient is willing to purchase 3 extra vials for DNA testing
Exclusions: The following are exclusion criteria:
- Diagnosis of chronic anovulation secondary to polycystic ovarian disease
- Diagnosis of endometrial insufficiency
- Clinical indication for PGD
- Testicular biopsy or aspiration procedures to obtain sperm
Contacts and Locations| United States, Colorado | |
| Colorado Center for Reproductive Medicine | |
| Lone Tree, Colorado, United States, 80124 | |
| United States, Connecticut | |
| Reproductive Medicine Associates of Connecticut | |
| Norwalk, Connecticut, United States, 06850 | |
| United States, Michigan | |
| Reproductive Medicine Associates of Michigan | |
| Troy, Michigan, United States, 48084 | |
| United States, New Jersey | |
| Reproductive Medicine Associates | |
| Morristown, New Jersey, United States, 07960 | |
| United States, New York | |
| Reproductive Medicine Associates of Vassar Brothers | |
| Fishkill, New York, United States, 12601 | |
| Reproductive Medicine Associates of New York | |
| New York, New York, United States, 10022 | |
| Principal Investigator: | Richard T Scott, MD | Reproductive Medicine Associates of New Jersey |
More Information
Additional Information:
No publications provided
| Responsible Party: | Reproductive Medicine Associates of New Jersey |
| ClinicalTrials.gov Identifier: | NCT01219517 History of Changes |
| Other Study ID Numbers: | RMA-00-18 |
| Study First Received: | October 8, 2010 |
| Last Updated: | January 22, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Reproductive Medicine Associates of New Jersey:
|
IVF embryo biopsy DNA fingerprinting SNP |
ClinicalTrials.gov processed this record on May 21, 2013